Drug Trial News

RSS

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX Technologies, Inc., a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer.

26 Jan 2016

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

The oral drug ivacaftor appears to be safe and could be beneficial to young children between the ages of 2 and 5 with a specific type of cystic fibrosis, according to new research published in The Lancet Respiratory Medicine journal.

22 Jan 2016

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

19 Jan 2016

Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

Experts from Children's Hospital Colorado (Children's Colorado) co-led a team of researchers in studying new approaches to reducing fall asthma exacerbations in pediatric patients.

18 Jan 2016

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina.

18 Jan 2016

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH's National Institute of Allergy and Infectious Diseases (NIAID).

17 Jan 2016

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).

13 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

A clinical trial using cholesterol-lowering treatment Simvastatin in people living with Parkinson's is getting underway in centres across the country -- with the hope that it could become one of a number of effective treatments available to treat Parkinson's.

12 Jan 2016

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine.

11 Jan 2016

TTUHSC researcher gets $3.82 million NIH grant to prepare Schistosomiasis Vaccine for clinical trials

Texas Tech University Health Sciences Center researcher Afzal A. Siddiqui, Ph.D., a Grover E. Murray Distinguished Professor at the TTUHSC School of Medicine, received a $3.82 million grant from the National Institutes of Health (NIH).

7 Jan 2016

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

The Sohn Conference Foundation today announced a $50,000 grant to support funding of a Phase 2 cutting-edge pediatric clinical trial from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) now extending to New York City.

6 Jan 2016

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Children and young adults with severe forms of epilepsy that does not respond to standard antiepileptic drugs have fewer seizures when treated with purified cannabinoid, according to a multi-center study led by researchers from UCSF Benioff Children's Hospital San Francisco.

6 Jan 2016

Drug Trial News

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Immunotherapy could be the future of cancer treatments

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

CTCA at Western announces launch of Phase II NivoPlus clinical trial

TTUHSC researcher gets $3.82 million NIH grant to prepare Schistosomiasis Vaccine for clinical trials

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News